{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:14:18Z","timestamp":1784589258529,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00277-022-04785-z","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T12:16:33Z","timestamp":1645013793000},"page":"1067-1075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["CD37 expression in follicular lymphoma"],"prefix":"10.1007","volume":"101","author":[{"given":"Takuro","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-3725","authenticated-orcid":false,"given":"Hiroaki","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Shimono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Yanagida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumasa","family":"Shimasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Moritsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"issue":"20","key":"4785_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"issue":"11","key":"4785_CR2","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1002\/cam4.1805","volume":"7","author":"R Muto","year":"2018","unstructured":"Muto R, Miyoshi H, Sato K, Furuta T, Muta H, Kawamoto K et al (2018) Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification. Cancer Med 7(11):5843\u20135858","journal-title":"Cancer Med"},{"issue":"5","key":"4785_CR3","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al (2004) Follicular Lymphoma International Prognostic Index. Blood 104(5):1258\u20131265","journal-title":"Blood"},{"issue":"27","key":"4785_CR4","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U et al (2009) Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555\u20134562","journal-title":"J Clin Oncol"},{"issue":"23","key":"4785_CR5","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33(23):2516\u20132522","journal-title":"J Clin Oncol"},{"issue":"9","key":"4785_CR6","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M et al (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16(9):1111\u20131122","journal-title":"Lancet Oncol"},{"issue":"5","key":"4785_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","volume":"21","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S et al (2012) Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 21(5):694\u2013708","journal-title":"Cancer Cell"},{"issue":"8","key":"4785_CR8","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/sj.leu.2403822","volume":"19","author":"S Barrena","year":"2005","unstructured":"Barrena S, Almeida J, Yunta M, L\u00f3pez A, Fern\u00e1ndez-Mosteir\u00edn N, Giralt M et al (2005) Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 19(8):1376\u20131383","journal-title":"Leukemia"},{"issue":"5","key":"4785_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1399-0039.2004.00321.x","volume":"64","author":"MD Wright","year":"2004","unstructured":"Wright MD, Moseley GW, van Spriel AB (2004) Tetraspanin microdomains in immune cell signalling and malignant disease. Tissue Antigens 64(5):533\u2013542","journal-title":"Tissue Antigens"},{"key":"4785_CR10","unstructured":"Schwartz-Albiez R, D\u00f6rken B, Hofmann W, Moldenhauer G (1988) The B cell-associated CD37 antigen (gp40\u201352). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 140(3): 905\u2013914"},{"issue":"7","key":"4785_CR11","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","volume":"110","author":"X Zhao","year":"2007","unstructured":"Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS et al (2007) Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110(7):2569\u20132577","journal-title":"Blood"},{"issue":"9","key":"4785_CR12","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1182\/blood-2013-07-512137","volume":"123","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP et al (2014) A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood 123(9):1302\u20131308","journal-title":"Blood"},{"issue":"26","key":"4785_CR13","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1182\/blood-2016-05-715094","volume":"128","author":"ZY Xu-Monette","year":"2016","unstructured":"Xu-Monette ZY, Li L, Byrd JC, abbar KJ, Manyam GC, Maria de Winde C, et al (2016) Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood 128(26):3083\u20133100","journal-title":"Blood"},{"issue":"11","key":"4785_CR14","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1097\/PAS.0000000000000969","volume":"42","author":"J Shimono","year":"2018","unstructured":"Shimono J, Miyoshi H, Yoshida N, Kato T, Sato K, Sugio T et al (2018) Analysis of GNA13 protein in follicular lymphoma and its association with poor prognosis. Am J Surg Pathol 42(11):1466\u20131471","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"4785_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/pin.12145","volume":"64","author":"H Miyoshi","year":"2014","unstructured":"Miyoshi H, Sato K, Yoshida M, Kimura Y, Kiyasu J, Ichikawa A et al (2014) CD5-positive follicular lymphoma characterized by CD25, MUM1, low frequency of t(14;18) and poor prognosis. Pathol Int 64(3):95\u2013103","journal-title":"Pathol Int"},{"issue":"3","key":"4785_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"4785_CR17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","volume":"132","author":"I Scarf\u00f2","year":"2018","unstructured":"Scarf\u00f2 I, Ormh\u00f8j M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA et al (2018) Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood 132(14):1495\u20131506","journal-title":"Blood"},{"issue":"12","key":"4785_CR18","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood.2019001185","volume":"134","author":"S Elfrink","year":"2019","unstructured":"Elfrink S, de Winde CM, van den Brand M, Berendsen M, Roemer MGM, Arnold F et al (2019) High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites. Blood 134(12):946\u2013950","journal-title":"Blood"},{"issue":"5","key":"4785_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s10637-018-0570-4","volume":"36","author":"A Stathis","year":"2018","unstructured":"Stathis A, Flinn IW, Madan S, Maddocks K, Freedman A, Weitman S et al (2018) Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation. Phase I Study Invest New Drugs 36(5):869\u2013876","journal-title":"Phase I Study Invest New Drugs"},{"issue":"17","key":"4785_CR20","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","volume":"25","author":"S Montoto","year":"2007","unstructured":"Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J et al (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25(17):2426\u20132433","journal-title":"J Clin Oncol"},{"issue":"1","key":"4785_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275\u2013282","journal-title":"Blood"},{"issue":"2","key":"4785_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1172\/JCI81041","volume":"126","author":"CM de Winde","year":"2016","unstructured":"de Winde CM, Veenbergen S, Young KH, Xu-Monette ZY, Wang XX, Xia Y et al (2016) Tetraspanin CD37 protects against the development of B cell lymphoma. J Clin Invest 126(2):653\u2013666","journal-title":"J Clin Invest"},{"issue":"1","key":"4785_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/eji.200838798","volume":"39","author":"heng KC, van Spriel AB, Gartlan KH,","year":"2009","unstructured":"heng KC, van Spriel AB, Gartlan KH, Sofi M, (2009) Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC. Eur J Immunol 39(1):50\u201355","journal-title":"Eur J Immunol"},{"issue":"5","key":"4785_CR24","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/eji.201242730","volume":"43","author":"KH Gartlan","year":"2013","unstructured":"Gartlan KH, Wee JL, Demaria MC, Nastovska R, Chang TM, Jones EL et al (2013) Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration. Eur J Immunol 43(5):1208\u20131219","journal-title":"Eur J Immunol"},{"issue":"20","key":"4785_CR25","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1182\/blood-2013-05-505685","volume":"122","author":"J Deckert","year":"2013","unstructured":"Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC et al (2013) A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 122(20):3500\u20133510","journal-title":"Blood"},{"issue":"11","key":"4785_CR26","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1093\/annonc\/mdv376","volume":"26","author":"A Conconi","year":"2015","unstructured":"Conconi A, Lobetti-Bodoni C, Montoto S, Lopez-Guillermo A, Coutinho R, Matthews J et al (2015) Life expectancy of young adults with follicular lymphoma. Ann Oncol 26(11):2317\u20132322","journal-title":"Ann Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04785-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04785-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04785-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T09:06:14Z","timestamp":1649408774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04785-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4785"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04785-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"23 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}